KIT and renal cell carcinoma: Additionally, Castillo et al. [10] had reported that sarcomatoid cells in 94.7% of RCC with sarcomatoid differentiation overexpressed CD117, suggesting the idea that tyrosine kinase inhibitor could be used for the therapy of CD117 positive RCC with sarcomatoid components patients.